Clinical trial NCT05529095: Sublingual Apomorphine in Refractory Restless Legs Syndrome
Official title: Open Label and Placebo-Controlled Assessment of Sublingual Apomorphine (Kynmobi) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Restless Legs Syndrome
Keywords: Refractory
Lead sponsor: The Methodist Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: Sumitomo Pharma America, Inc.
First posted: 2022-09-06
Enrollment: 16
Sex: ALL
Minimum age (years): 21
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses.

Detailed description: This is an open label, with a short placebo-controlled portion trial using sublingual apomorphine (Kynmobi) in RLS patients inadequately treated with standard therapy, defined by an IRLS \> 15 and report of breakthrough symptoms.

At the initial visit, subjects will undergo all baseline and exploratory assessments and be given their first drug dose of 10 mg. They will be monitored for 60 minutes after dose. Subjects orthostatic blood pressure will be taken before ingestion, then 10, 20, 30, and 45 minutes after ingestion. Over the next 4 weeks, subjects will titrate Kynmobi to find optimal dose. Subjects will be instructed to take at least 2 doses before determining if further titration is needed.

At week 4, subjects will return for exploratory assessments. Subjects will be given a randomized study drug packet containing 2 placebos and 2 drug doses. Subjects will be told that 0-4 doses may be placebo or drug. Subjects will have 4 weeks to complete randomization doses. It is anticipated subjects will complete randomization sooner, so they will be given 23 doses of study drug (1 dose per 24 hours for 23 extra days until next visit).

At week 8, subjects will return for exploratory assessments and be given an additional 74 dosed strips. They will return at week 16 for a final visit and undergo exploratory assessments, followed by a safety call two weeks later.

From weeks 0-8, subjects are able to continue their scheduled RLS medications. From weeks 8-16, subjects may make changes to their RLS medications as mutually agreed upon with investigator.

Several questionnaire assessments will be conducted throughout the study to monitor subjects. Subjects will complete the International RLS Rating Scale (IRLS), Restless Legs Syndrome - 6 Scale (RLS - 6), RLS Quality of Life Questionnaire (RLSQoL), RLS Augmentation Scale, Fatigue Severity Scale (FSS), Hamilton Depression Scale (HDS), Clinical Global Impressions (CGI), and Clinical Global Impressions-Change (CGI-C).

Eligibility criteria: Inclusion Criteria:

* Idiopathic RLS diagnosed by standard criteria, with an IRLS \> 15 while taking at least 1 RLS medication
* Stable RLS medications for at least 2 weeks prior to study entry

Exclusion Criteria:

* Concurrent untreated sleep disorders, not felt to be able stable
* Subjects with any significant, unstable cardiovascular, liver, lung, renal. psychiatric, or neurological diseases (not including RLS)
* Any medical or psychiatric comorbidity that, in the opinion of the investigator, would make study compliance difficult to achieve
* Intravenous iron within 4 weeks of study entry
* Breast feeding or pregnancy determined by urine pregnancy test in subjects where pregnancy is a possibility (pre-menopausal, sexually active women)
* Subjects with previous allergic reaction to apomorphine or sulfate sensitivity
* Subjects currently taking 5HT3 antagonists

Primary outcomes:
measure: Visual Analogue Scale of Improvement
timeFrame: Weeks 4 - 8
Secondary outcomes:
measure: International RLS Rating Scale (IRLS)
timeFrame: Baseline, 4 weeks, 8 weeks, and 16 weeks
measure: The Restless Legs Syndrome - 6 Scale (RLS-6)
timeFrame: Baseline, 4 weeks, 8 weeks, and 16 weeks
measure: Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL)
timeFrame: Baseline, 4 weeks, 8 weeks, and 16 weeks
measure: Hamilton Depression Scale (HDS)
timeFrame: Baseline, 4 weeks, 8 weeks, and 16 weeks
measure: Epworth Sleepiness Scale (ESS)
timeFrame: Baseline, 4 weeks, 8 weeks, and 16 weeks
measure: Clinical Global Impressions - Change
timeFrame: 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 12 weeks, 16 weeks, and 18-20 weeks
Other outcomes:
Locations:
city: Houston
country: United States
facility: Houston Methodist Hospital
state: Texas
Study officials:
affiliation: The Methodist Hospital Research Institute
name: William Ondo, MD
role: PRINCIPAL_INVESTIGATOR
References: